PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
31.77%
Cash & equivalents yoy growth below half of RVPH's 56277.26%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
31.77%
Below half of RVPH's 56277.26%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.02%
Below half of RVPH's 22889.11%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
13.80%
Higher PP&E (Net) Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.28%
Below half of RVPH's -99.99%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
31.41%
Below half of RVPH's -74.59%. Michael Burry sees a potential red flag for stagnation or capital shortage.
2.77%
Higher Accounts Payable Growth compared to RVPH's zero value, indicating worse performance.
1023.68%
Higher Short-Term Debt Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-1.85%
Both RVPH and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
1.86%
Less than half of RVPH's 80.97%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.95%
Less than half of RVPH's 15.12%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-0.43%
Less than half of RVPH's -69.54%. David Dodd sees far fewer liability expansions relative to competitor.
28.57%
Less than half of RVPH's -100.00%. David Dodd sees fewer share issuances vs. competitor.
-2.84%
Below half RVPH's -11308.39%. Michael Burry suspects major net losses or high dividends vs. competitor.
100.00%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
34.98%
0.5-0.75x RVPH's 48.59%. Martin Whitman is wary of lagging equity growth vs. competitor.
31.41%
Below half RVPH's -6.54%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-15.85%
Higher Total Debt Growth compared to RVPH's zero value, indicating worse performance.
-32.66%
Less than half of RVPH's -56277.26%. David Dodd sees better deleveraging or stronger cash buildup than competitor.